Pipeline
Cumulus Oncology focuses its efforts on identifying opportunities that meet specific criteria, including definitive and validated scientific rationale, a clear unmet medical need and market, and evidence of VC and Pharma interest to fuel deal flow. Cumulus collaboratively curates the development of its assets with selected platform technology partners. We are both platform and modality agnostic and start with the science underpinning target validation.
Risk share & asset curation partners
Data science & Bioinformatics
Deep interrogation of relevant data sets and application of platform technologies to ensure:
- Focus on appropriate patient sub-groups
- Deep understanding of target expression profiles and relevance to causality
- In silico target validation
- Identification of novel targets
Meet our spin-outs
Cumulus has curated and created a number of oncology biotech spin-out companies, with further other opportunities in development
